Detalles de la búsqueda
1.
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
J Cell Mol Med
; 28(9): e18342, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38693852
2.
Epigenetic Priming and Development of New Combination Therapy Approaches.
Methods Mol Biol
; 2684: 259-281, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37410240
3.
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Genes (Basel)
; 12(2)2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33670166
4.
Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment.
Cancers (Basel)
; 13(6)2021 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33803654
5.
Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.
Cancers (Basel)
; 12(4)2020 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32260145
6.
Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
Radiother Oncol
; 137: 24-31, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31048234
7.
RNA Profiling of the Human and Mouse Spinal Cord Stem Cell Niches Reveals an Embryonic-like Regionalization with MSX1+ Roof-Plate-Derived Cells.
Stem Cell Reports
; 12(5): 1159-1177, 2019 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31031189
8.
Corrigendum to "Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens" [Radiother. Oncol. 137 (2019) 24-31].
Radiother Oncol
; 183: 109619, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37001220
Resultados
1 -
8
de 8
1
Próxima >
>>